Skip to contentpdufa.bio

piclidenoson pivotal

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

piclidenoson pivotal is a Can-Fite BioPharma Ltd. program in moderate-to-severe plaque psoriasis. Its next catalyst is a Readout in Q1 2027.

CANF catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: moderate-to-severe plaque psoriasis. Sponsor: Can-Fite BioPharma Ltd. (CANF). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027CANF

Questions

When is piclidenoson pivotal's next FDA decision or readout?

The next tracked catalyst for piclidenoson pivotal is a Readout in Q1 2027.

What happened at piclidenoson pivotal's most recent FDA decision?

No FDA decision for piclidenoson pivotal is in our archive yet.

What is piclidenoson pivotal used for?

In our records piclidenoson pivotal is under review or in development for moderate-to-severe plaque psoriasis.

Who makes piclidenoson pivotal?

Can-Fite BioPharma Ltd. (CANF).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.